National Cancer Institute (nci)

This study tests whether adjusting chemotherapy doses for each patient can improve outcomes after a stem cell transplant for blood cancers caused by a RUNX1 gene mutation. Up to 98 people aged 4 to 70 with these cancers will receive a transplant from a half-matched donor. The goa…

This trial tests a new approach for people with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own myeloid cells, a type of immune cell, which are genetically modified in a lab to produce a cancer-fighting protein called IL…

This study tests a new drug called SX-682 (a tablet) combined with the chemotherapy docetaxel in people whose head/neck, salivary gland, or prostate cancer has spread or returned after treatment. The goal is to find the right dose and see if the combination shrinks tumors. About …

This trial tests whether a drug called carfilzomib, given directly to the liver through an implanted pump, is safe for people whose colon, adrenal, or bile duct cancer has spread to the liver and persists after prior pump therapy. Participants receive weekly infusions of the drug…

This early-phase trial tests a new therapy for people with advanced small cell lung cancer or similar neuroendocrine cancers that have not responded to prior treatment. The approach involves collecting a patient's own immune cells, modifying them in a lab to recognize a protein c…

This phase 2 trial tests a combination of a vaccine (TriAdeno) and an immune-boosting drug (N-803) in 52 men with early-stage, low- or medium-risk prostate cancer who are currently on active surveillance. The vaccine targets three proteins found in prostate cancer cells, while N-…

This phase II trial tests whether combining bevacizumab, a drug that limits blood vessel growth, with PRGN-2012, a vaccine-based therapy, can help adults with recurrent respiratory papillomatosis (RRP) avoid needing more surgeries. RRP causes wart-like growths in the airway that …

This Phase II trial tests whether an immune-boosting drug (N-803) alone or combined with a vaccine (ETBX-071) can lower PSA levels in men whose prostate cancer has returned after targeted radiation therapy. Participants receive up to eight cycles of treatment and are followed for…

This phase II trial tests whether adding venetoclax to standard chemotherapy and stem cell transplant, followed by venetoclax maintenance, helps adults with acute myeloid leukemia (AML) stay in remission longer. About 244 participants will receive either venetoclax or a placebo a…

This study tests whether adding epoetin alfa or emavusertib to luspatercept helps people with low-risk myelodysplastic syndrome (MDS) and anemia. MDS is a bone marrow disorder that leads to low blood counts. The goal is to see if these combinations improve red blood cell producti…

This phase 2 trial tests whether adding olutasidenib to standard treatments helps people with IDH1-mutated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). For AML, the standard is a chemotherapy pill plus venetoclax; for higher-risk MDS, it's the chemotherapy pill…

This study tests adding a new drug, iberdomide, to standard chemoimmunotherapy for children and young adults (ages 1-30) whose neuroblastoma has returned, not responded, or worsened after prior treatment. The goal is to see if the combination is safe and works better at controlli…

This early-phase trial tests the safety and best dose of glofitamab, an antibody that helps the immune system attack cancer, when given alongside standard chemotherapy (R-CHOP and R-DHAP) for people with untreated mantle cell lymphoma. Sixteen adults aged 18 to 75 with stage II b…

This phase 2 trial tests whether adding tirzepatide (a weight-loss injection) to a levonorgestrel intrauterine device (LNG-IUD) can eliminate precancerous or early-stage endometrial cancer in overweight or obese women. About 55 women who want to avoid hysterectomy will receive bo…

This trial tests whether adding the bispecific antibody glofitamab to standard chemoimmunotherapy can improve outcomes for people with Burkitt lymphoma or high-grade B-cell lymphoma with MYC and BCL2 rearrangements. These are fast-growing cancers that can be hard to treat. The st…

This early-phase trial will test the safety and feasibility of adding the experimental drug glofitamab to standard chemoimmunotherapy (R-CHOP) in 15 people newly diagnosed with HIV-associated large B-cell lymphoma. Glofitamab is a bispecific antibody that helps the immune system …

This phase 2 trial tests a new drug called brenetafusp (IMC-F106C) in people with rare cancers—synovial sarcoma and myxoid liposarcoma—that have spread or cannot be surgically removed. The drug is a type of immunotherapy designed to guide the body's immune cells to attack cancer …

This phase III trial compares the immunotherapy drug pembrolizumab to active surveillance (no treatment) after kidney cancer surgery in patients with non-clear cell renal cell carcinoma, a less common type of kidney cancer. The goal is to see if pembrolizumab can help the immune …

This phase II trial compares a new two-drug combination (sacituzumab govitecan plus bevacizumab) against standard chemotherapy (carboplatin, liposomal doxorubicin, and bevacizumab) in 87 women with platinum-sensitive ovarian cancer that has progressed after PARP inhibitor mainten…

This clinical trial is for people whose Hodgkin lymphoma has returned or not responded to first treatment. It has two parts: one for standard-risk patients testing a combination of targeted drugs (brentuximab vedotin and nivolumab) plus radiation, and another for high-risk patien…

This early-stage trial tests whether combining two drugs—selumetinib and DS-8201a—can safely shrink or control advanced pancreatic cancer that has a specific genetic change (KRAS mutation) and a protein called HER2. About 31 adults with cancer that cannot be removed by surgery or…

This early-phase trial tests a new combination for recurrent glioblastoma, a fast-growing brain tumor. The treatment pairs Actimab-A, a radioactive antibody that seeks out cancer cells, with cemiplimab, an immunotherapy that helps the immune system attack tumors. About 30 adults …

This Phase 2 trial tests whether adding other drugs to standard chemotherapy can eliminate leftover leukemia cells in adults aged 18-59 before a stem cell transplant. Participants who still have detectable disease after initial treatment will receive one of four drug combinations…

This study tests a vaccine called SurVaxM in 80 current or former heavy smokers at high risk for lung cancer. The vaccine trains the immune system to recognize and attack cells that produce a protein called survivin, which is common in cancer cells. The goal is to see if the vacc…

This study screens up to 1,000 people with personal or family histories of certain cancers to see if they qualify for ongoing genetics research at the National Cancer Institute. Participants fill out a 15-20 minute online survey about their health and family history. No treatment…